News | Proton Therapy | September 06, 2016

IBA and RaySearch Join Forces to Advance Adaptive Proton Therapy

Strategic alliance will work to integrate RaySearch’s RayCare oncology information system with IBA’s proton therapy delivery systems

IBA, RaySearch, adaptive proton therapy, RayCare oncology information system, strategic alliance

September 6, 2016 — IBA (Ion Beam Applications S.A.) and RaySearch Laboratories have entered into a long-term strategic alliance to combine their respective technologies and advance adaptive proton therapy.

As part of the collaboration, the RayCare oncology information system, which is currently in development at RaySearch, will be customized for optimal use together with the IBA delivery solutions. In both RayStation and RayCare, as well as in the IBA delivery solutions, joint features, dedicated software interfaces and modified graphical user interface components will allow for a close and seamless workflow integration with optimized performances. The result will be a complete turnkey solution for all software and hardware needed to deliver adaptive proton therapy treatment.

Proton therapy is one of the most precise forms of radiation therapy: Targets can be pinpointed with the optimal radiation dose, while adjacent tissue is spared to a much higher degree than with conventional radiation therapy. The technique is growing in popularity worldwide, and studies are converging to point towards the fact that approximately 20 percent of radiation therapy patients could benefit from proton therapy while only 1 percent receive it today.

For more information: www.raysearchlabs.com, www.iba-worldwide.com

Related Content

DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Information Technology | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
Accuray Radixact

Accuray Radixact

Feature | Radiation Therapy | May 29, 2019 | By Jeff Zagoudis
While radiation therapy as a disciplin
Sponsored Content | Case Study | Radiation Therapy | May 29, 2019
The so-called “Grey Tsunami” of baby boomers using healthcare services isn’t taking the Radiation Medicine Program at